EUSA Pharma (EUSA), a global biopharmaceutical company with a focus on oncology and rare disease, today announced the appointment of Jeffrey S. Hackman as President of its United States’ operations. Mr Hackman will lead a major expansion of the company’s US organization, as EUSA completes its transatlantic commercial infrastructure.
| BOSTON and HEMEL HEMPSTED, England, /PRNewswire/ -- - EUSA to Open New US Headquarters in Boston, MA - - Significant US Expansion to Complete EUSA’s Transatlantic Commercial Platform - EUSA Pharma (EUSA), a global biopharmaceutical company with a focus on oncology and rare disease, today announced the appointment of Jeffrey S. Hackman as President of its United States’ operations. Mr Hackman will lead a major expansion of the company’s US organization, as EUSA completes its transatlantic commercial infrastructure. As part of its growth plans in the United States, EUSA is establishing a new headquarters in Boston, MA, and rapidly growing its sales, marketing, market access and medical teams. In the coming weeks, the company intends to launch a new sales force targeting key oncology and rare disease centers across the country, supported by a full medical and commercial team. Jeffrey S. Hackman brings to EUSA 30 years’ commercial pharmaceutical experience, including extensive expertise gained in the oncology field. He has a strong track record of building and leading commercial organizations and delivering business growth. He joins EUSA from rare disease company Novelion Therapeutics, where he was acting CEO. Prior to this he was Senior VP and Head of US Internal Medicine / Oncology at Shire Inc., following a period leading the company’s US oncology franchise. Previously, he was responsible for establishing the North American oncology commercial division for Baxalta, following several years leading US commercial operations for Sigma Tau. He also held senior roles in a number of other pharmaceutical companies. Lee Morley, EUSA Pharma’s Chief Executive Officer, said, “We are delighted to welcome Jeff to EUSA to lead our expansion in the United States and complete our strategic transatlantic commercial platform. EUSA is well established as a successful oncology and rare disease business in Europe, and we have the same ambition for our company in the United States. In the coming weeks, we plan to launch our significantly expanded commercial team, providing a platform to grow our in-house products and attract additional products from third parties.” Jeffrey S. Hackman, EUSA Pharma’s President, United States, said, “I am thrilled to join EUSA at this exciting time for the company. Since its establishment in 2015, the company has made tremendous progress and I look forward to playing a key role in its rapid growth in the US. EUSA is gaining an enviable reputation in the oncology and rare disease markets, and I am excited at the prospect of building a successful US organization as part of the company’s global ambitions.” About EUSA Pharma Contacts Rob Budge SOURCE EUSA Pharma |
